Global
   
Include All CSL Behring Country Sites

Investors

CSL Share Price



Price Chart 
View CSL's share price performance over a 12 month period.

 


ASX Releases

Subscribe to News Alert to receive the latest updates about CSL.

Further Information

The ASX website provides the following information about CSL :

18/08/2010
Full-year results for 2009/10
CSL Limited today announced a profit after tax of $1,053 million for the twelve months ended 30 June 2010. More.

17/02/2010
Half-year results announcement for 2009/10
CSL Limited today announced its first half result for period ended 31 December 2009. More.

23/12/2009
CSL Limited and National Blood Authority sign new Australian Fractionation Agreement
CSL Limited (ASX: CSL) announced today that it has signed an agreement with the National Blood Authority, acting on behalf of both State and Commonwealth Governments, to continue to provide the Australian community with safe, secure and affordable plasma therapeutic products. More.

08/12/2009
CHANGES TO CSL SENIOR EXECUTIVE GROUP
CSL Limited (ASX:CSL), Australia’s leading biopharmaceutical company, announced today a number of changes in its organisation structure and its senior executive group, within the context that Dr Brian McNamee would be continuing as CEO and Managing Director for at least a further three to four years. More.

19/08/2009
Full-year results for 2008/09
CSL Limited today announced a profit after tax of $1.15 billion for the twelve months ended 30 June 2009, up 63% when compared to the twelve months ended 30 June 2008. More.

>> Prior ASX Releases


Investors Contact

Mark Dehring
Director of Investor Relations
Phone: +61 3 9389 2818
Email: mark.dehring@csl.com.au
45 Poplar Rd
Parkville
Victoria 3052
Australia